{"id":59658,"date":"2020-06-10T23:00:51","date_gmt":"2020-06-11T03:00:51","guid":{"rendered":"https:\/\/recursing-golick.147-182-135-0.plesk.page\/?p=59658"},"modified":"2020-06-11T21:14:05","modified_gmt":"2020-06-12T01:14:05","slug":"un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang","status":"publish","type":"post","link":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/","title":{"rendered":"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang"},"content":{"rendered":"<p><span lang=\"FR-CA\">Le 10 juin 2020 | Orlando, Floride, \u00c9tats-Unis | Les communications externes de la division centre-floridienne d\u2019<i>AdventHealth<\/i><\/span><\/p>\n<p><span lang=\"FR-CA\">Les m\u00e9decins d\u2019<i>AdventHealth<\/i> sont les premiers au monde \u00e0 offrir un traitement novateur aux patients atteints de certains cancers du sang qui ont \u00e9puis\u00e9 tous les autres types de traitements.<\/span><\/p>\n<p><span lang=\"FR-CA\">En effet, le traitement \u00e0 lymphocytes T sp\u00e9cifiques \u00e0 un antig\u00e8ne, sujet d\u2019un essai clinique d\u2019<i>AdventHealth<\/i>d\u2019Orlando, utilise des cellules immunitaires pour cibler les cellules canc\u00e9reuses, offrant ainsi \u00e0 des patients qui souffrent de certains types de leuc\u00e9mies my\u00e9loblastiques aigu\u00ebs (LMA) et de syndromes my\u00e9lodysplastiques (SMD) ce qui est souvent leur derni\u00e8re chance de gu\u00e9rison.<\/span><\/p>\n<p><span lang=\"FR-CA\">Le premier patient \u00e0 recevoir ce traitement a \u00e9t\u00e9 trait\u00e9 \u00e0 la fin avril \u00e0 <i>AdventHealth <\/i>d\u2019Orlando et se r\u00e9tablit actuellement \u00e0 la maison. Il sera suivi pendant plusieurs mois pour d\u00e9terminer l\u2019efficacit\u00e9 du traitement.<\/span><\/p>\n<p><span lang=\"FR-CA\">D\u2019apr\u00e8s le <i>National Cancer Institute<\/i>, plus de 19\u00a0000\u00a0personnes recevront un diagnostic de LMA cette ann\u00e9e aux \u00c9tats-Unis et plus de 11\u00a0000 d\u2019entre eux succomberont \u00e0 la maladie. Le taux de survie de cinq ans pour la LMA est de 28,7\u00a0% alors que le m\u00eame taux de survie pour la leuc\u00e9mie en g\u00e9n\u00e9ral est de 63,7\u00a0%.<\/span><\/p>\n<p><span lang=\"FR-CA\">Le nombre de personnes qui re\u00e7oivent chaque ann\u00e9e un diagnostic de SMD au pays est incertain, mais il est estim\u00e9 \u00e0 au moins 10\u00a0000 selon l\u2019<i>American Cancer Society<\/i>.<\/span><\/p>\n<p><span lang=\"FR-CA\">D\u2019apr\u00e8s le Dr Juan Carlos Varela, h\u00e9mato-oncologue d\u2019<i>AdventHealth<\/i> et investigateur principal de cet essai clinique, \u00ab\u00a0Le plus grand avantage d\u2019un traitement d\u2019immunoth\u00e9rapie comme celui-ci, c\u2019est qu\u2019il s\u2019agit d\u2019une fa\u00e7on adaptable et personnalis\u00e9e de traiter le cancer des patients qui n\u2019ont plus d\u2019autres options. Le taux de rechute suivant les formes traditionnelles de traitement de ces patients tourne autour de 40\u00a0%, cette rechute \u00e9tant la cause premi\u00e8re de d\u00e9c\u00e8s chez cette population de patients. Leurs options sont tr\u00e8s limit\u00e9es, donc le besoin d\u2019un traitement comme celui-ci qui puisse leur sauver la vie est urgent.\u00a0\u00bb<\/span><\/p>\n<p><span lang=\"FR-CA\">Les lymphocytes T sp\u00e9cifiques \u00e0 un antig\u00e8ne sont fabriqu\u00e9s en soutirant des globules blancs au donneur qui avait d\u00e9j\u00e0 donn\u00e9 des cellules souches au patient, g\u00e9n\u00e9rant ainsi des cellules immunitaires qui s\u2019attaquent sp\u00e9cifiquement aux tumeurs, puis en transfusant les cellules g\u00e9n\u00e9r\u00e9es dans le syst\u00e8me sanguin du patient. Les lymphocytes T sp\u00e9cifiques \u00e0 un antig\u00e8ne sont capables d\u2019attaquer des cellules canc\u00e9reuses sp\u00e9cifiques.<\/span><\/p>\n<p><span lang=\"FR-CA\">\u00ab\u00a0En \u00e9tant les premiers au monde \u00e0 lancer ce traitement et en ayant l\u2019investigateur principal dans notre \u00e9quipe, nous t\u00e9moignons de notre d\u00e9vouement envers la m\u00e9decine personnalis\u00e9e, qui est d\u2019ailleurs l\u2019avenir du traitement des cancers, a dit le Dr Mark A. Socinski, directeur m\u00e9dical administratif de l\u2019Institut d\u2019oncologie d\u2019<i>AdventHealth<\/i>. Nous sommes enthousiastes de proposer ce traitement innovateur \u00e0 nos patients, leur donnant une autre chance de vivre sans s\u2019\u00e9loigner de la maison.\u00a0\u00bb<\/span><\/p>\n<p><span lang=\"FR-CA\">L\u2019essai clinique du traitement \u00e0 lymphocytes T sp\u00e9cifiques \u00e0 un antig\u00e8ne et le programme de greffes de cellules souches et de moelle osseuse sont possibles gr\u00e2ce au g\u00e9n\u00e9reux soutien des donneurs de la collectivit\u00e9, y compris la Fondation d\u2019<i>AdventHealth<\/i> du centre de la Floride.<\/span><\/p>\n<p><span lang=\"FR-CA\">Traduction\u00a0: Marie-Mich\u00e8le Robitaille<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 10 juin 2020 | Orlando, Floride, \u00c9tats-Unis | Les communications externes de la division centre-floridienne d\u2019AdventHealth Les m\u00e9decins d\u2019AdventHealth sont les premiers au monde \u00e0 offrir un traitement novateur&#8230;<\/p>\n","protected":false},"author":3,"featured_media":59634,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[18,19],"tags":[],"class_list":["post-59658","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles-de-leglise-mondiale","category-rss-francais"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang - \u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang - \u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division\" \/>\n<meta property=\"og:description\" content=\"Le 10 juin 2020 | Orlando, Floride, \u00c9tats-Unis | Les communications externes de la division centre-floridienne d\u2019AdventHealth Les m\u00e9decins d\u2019AdventHealth sont les premiers au monde \u00e0 offrir un traitement novateur...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-11T03:00:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-12T01:14:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/interamerica.org\/wp-content\/uploads\/2020\/06\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"libna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"libna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/\"},\"author\":{\"name\":\"libna\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/#\\\/schema\\\/person\\\/29998f2bc2d8bd0d38662909289b54f1\"},\"headline\":\"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang\",\"datePublished\":\"2020-06-11T03:00:51+00:00\",\"dateModified\":\"2020-06-12T01:14:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/\"},\"wordCount\":577,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/interamerica.org\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg\",\"articleSection\":[\"Nouvelles de l'\u00c9glise mondiale\",\"RSS Fran\u00e7ais\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/\",\"url\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/\",\"name\":\"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang - \u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/interamerica.org\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg\",\"datePublished\":\"2020-06-11T03:00:51+00:00\",\"dateModified\":\"2020-06-12T01:14:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/#\\\/schema\\\/person\\\/29998f2bc2d8bd0d38662909289b54f1\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#primaryimage\",\"url\":\"https:\\\/\\\/interamerica.org\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg\",\"contentUrl\":\"https:\\\/\\\/interamerica.org\\\/wp-content\\\/uploads\\\/2020\\\/06\\\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg\",\"width\":800,\"height\":533,\"caption\":\"Une photo d'AdventHealth.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/2020\\\/06\\\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/\",\"name\":\"\u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/interamerica.org\\\/fr\\\/#\\\/schema\\\/person\\\/29998f2bc2d8bd0d38662909289b54f1\",\"name\":\"libna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7c5bd30ae4b47a9ba3c856590957fd1d96dc588bf3ac05719d247e126840331f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7c5bd30ae4b47a9ba3c856590957fd1d96dc588bf3ac05719d247e126840331f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7c5bd30ae4b47a9ba3c856590957fd1d96dc588bf3ac05719d247e126840331f?s=96&d=mm&r=g\",\"caption\":\"libna\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang - \u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/","og_locale":"fr_FR","og_type":"article","og_title":"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang - \u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division","og_description":"Le 10 juin 2020 | Orlando, Floride, \u00c9tats-Unis | Les communications externes de la division centre-floridienne d\u2019AdventHealth Les m\u00e9decins d\u2019AdventHealth sont les premiers au monde \u00e0 offrir un traitement novateur...","og_url":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/","og_site_name":"\u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division","article_published_time":"2020-06-11T03:00:51+00:00","article_modified_time":"2020-06-12T01:14:05+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/interamerica.org\/wp-content\/uploads\/2020\/06\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg","type":"image\/jpeg"}],"author":"libna","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"libna","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#article","isPartOf":{"@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/"},"author":{"name":"libna","@id":"https:\/\/interamerica.org\/fr\/#\/schema\/person\/29998f2bc2d8bd0d38662909289b54f1"},"headline":"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang","datePublished":"2020-06-11T03:00:51+00:00","dateModified":"2020-06-12T01:14:05+00:00","mainEntityOfPage":{"@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/"},"wordCount":577,"commentCount":0,"image":{"@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#primaryimage"},"thumbnailUrl":"https:\/\/interamerica.org\/wp-content\/uploads\/2020\/06\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg","articleSection":["Nouvelles de l'\u00c9glise mondiale","RSS Fran\u00e7ais"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/","url":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/","name":"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang - \u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division","isPartOf":{"@id":"https:\/\/interamerica.org\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#primaryimage"},"image":{"@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#primaryimage"},"thumbnailUrl":"https:\/\/interamerica.org\/wp-content\/uploads\/2020\/06\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg","datePublished":"2020-06-11T03:00:51+00:00","dateModified":"2020-06-12T01:14:05+00:00","author":{"@id":"https:\/\/interamerica.org\/fr\/#\/schema\/person\/29998f2bc2d8bd0d38662909289b54f1"},"breadcrumb":{"@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#primaryimage","url":"https:\/\/interamerica.org\/wp-content\/uploads\/2020\/06\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg","contentUrl":"https:\/\/interamerica.org\/wp-content\/uploads\/2020\/06\/antigen-specific2520t-cell2520therapy2520team2520prior2.jpg","width":800,"height":533,"caption":"Une photo d'AdventHealth."},{"@type":"BreadcrumbList","@id":"https:\/\/interamerica.org\/fr\/2020\/06\/un-nouveau-traitement-dimmunotherapie-offert-en-essai-clinique-aux-patients-dadventhealth-atteints-de-certains-types-de-cancers-du-sang\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/interamerica.org\/fr\/"},{"@type":"ListItem","position":2,"name":"Un nouveau traitement d\u2019immunoth\u00e9rapie offert en essai clinique aux patients d\u2019AdventHealth atteints de certains types de cancers du sang"}]},{"@type":"WebSite","@id":"https:\/\/interamerica.org\/fr\/#website","url":"https:\/\/interamerica.org\/fr\/","name":"\u00c9glise Adventiste Du Septieme Jour - Inter Am\u00e9rique Division","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/interamerica.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/interamerica.org\/fr\/#\/schema\/person\/29998f2bc2d8bd0d38662909289b54f1","name":"libna","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/7c5bd30ae4b47a9ba3c856590957fd1d96dc588bf3ac05719d247e126840331f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7c5bd30ae4b47a9ba3c856590957fd1d96dc588bf3ac05719d247e126840331f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7c5bd30ae4b47a9ba3c856590957fd1d96dc588bf3ac05719d247e126840331f?s=96&d=mm&r=g","caption":"libna"}}]}},"_links":{"self":[{"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/posts\/59658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/comments?post=59658"}],"version-history":[{"count":0,"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/posts\/59658\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/media\/59634"}],"wp:attachment":[{"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/media?parent=59658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/categories?post=59658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/interamerica.org\/fr\/wp-json\/wp\/v2\/tags?post=59658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}